Live Q&A: Hitting Refresh on Excessive Daytime Sleepiness: Managing Patients with Narcolepsy and Idiopathic Hypersomnia
Premiere Date: Wednesday, July 14, 2021This activity offers CE credit for:
- Physicians (CME)
- Pharmacists (ACPE)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Thursday, July 14, 2022
Note: Credit Is No Longer Available
 | Richard K. Bogan, MD, FCCP, FAASM Associate Clinical Professor University of South Carolina Medical School, Columbia, SC Medical University of South Carolina, Charleston, SC Principal, Bogan Sleep Consultants, LLC Charleston, SC |
Central disorders of hypersomnia such as narcolepsy and idiopathic hypersomnia (IH) can be debilitating as both disorders are characterized to excessive daytime sleepiness (EDS) which conveys a high decree of disability and burden. While there are safe, effective therapies that promote sustained reduction of symptoms in narcolepsy, there is often a failure to implement them in a timely manner. Moreover, there are currently no FDA-approved treatments for IH, making effective management a challenge. As patients with narcolepsy or IH often experience persistent EDS despite traditional treatment, there is a need for education on identifying and implementing effective novel therapies.
This live question and answer session is your opportunity to ask questions based on the CME Outfitters virtual symposium where faculty focused on the spectrum of EDS across the subtypes of narcolepsy, strategies to apply data from recent clinical trials to treatment decision-making, and the impact of emerging agents for the management of EDS in patients with IH. To view the full activity ahead of this live Q&A, click here.
At the end of this CE activity, participants should be able to:
- Differentiate the spectrum of EDS across the subtypes of narcolepsy (type 1, type 2).
- Apply data from recent clinical trials to treatment decision-making in patients with narcolepsy.
- Evaluate the impact of emerging agents for the management of EDS in patients with IH.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Differentiate the spectrum of EDS across the subtypes of narcolepsy (type 1, type 2).
- Explain how data from recent clinical trials to treatment decision-making in patients with narcolepsy.
- Evaluate the impact of emerging agents for the management of EDS in patients with IH.
Supported by an educational grant from Jazz Pharmaceuticals, Inc.
Sleep specialists, physicians, nurse practitioners, PAs, nurses, and pharmacists
CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-094-L01-P
Type: knowledge-based
Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by the ACCME or a recognized state medical society.
Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Bogan reports that he receives grants from Axsome Therapeutics, Inc.; Eisai Inc.; Flamel Technologies; Fresca Medical, Inc.; Harmony Biosciences, LLC; Idorsia Pharmaceuticals; Jazz Pharmaceuticals, Inc.; Merck & Co., Inc.; Philips; Suven Life Sciences; and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc.; and Takeda Pharmaceuticals, U.S.A., Inc. He is on the speakers bureau for Eisai Inc.; Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc.
Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
Evan Luberger (planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Sharon Tordoff (planning committee) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report..
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMQ-115-071421-43
